BioLineRx is a biopharmaceutical development company focused on building a portfolio of products to address unmet medical needs or offer advantages over currently available therapies. The company’s portfolio presently consists of six clinical stage candidates, in addition to products in various pre-clinical development stages. The company’s business model is based on the acquisition of molecules, primarily from biotechnological incubators and academic institutions. For more information, visit the company’s Web site at www.biolinerx.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: